Organon & Co. (OGN)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 6,532 | 6,304 | 6,174 | 6,263 | 6,403 | 6,216 | 6,127 | 6,135 |
| Operating profit | $m | 1,285 | 1,182 | ||||||
| Net profit | $m | 2,160 | 1,351 | 917 | 1,023 | 864 | 187 | 209 | 891 |
| EPS reported | $ | 0.72 | 0.77 | ||||||
| Operating cashflow per share | $ | 2.70 | 2.81 | ||||||
| Capex per share | $ | 0.62 | 0.91 | ||||||
| FCF per share | $ | 2.07 | 1.90 | ||||||
| Free cash flow | $m | 538 | 498 | ||||||
| Net debt | $m | 8,110 | 7,421 | ||||||
| Book value equity | $m | 752 | 1,006 | ||||||
| Book value per share | $ | 2.88 | 3.72 | ||||||
| Number of shares | m | 260.76 | 270.45 | ||||||
| DPS (TTM paid) | $ | 0.34 | 0.08 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 9.96 | 17.83 | ||||||
| P/B LTM | x | 2.47 | 1.85 | ||||||
| P/S LTM | x | 0.30 | 0.30 | ||||||
| P/FCF LTM | x | 3.46 | 3.74 | ||||||
| EV/EBITDA LTM | x | 7.87 | 7.72 | ||||||
| EV/Sales LTM | x | 1.62 | 1.80 | ||||||
| Earnings Yield LTM | % | +10.04% | +5.61% | ||||||
| FCF Yield | % | +28.92% | +26.77% | ||||||
| Quality | |||||||||
| ROE | % | +24.87% | +23.44% | ||||||
| ROIC | % | +5.37% | +4.73% | ||||||
| Operating margin | % | +20.67% | +19.29% | ||||||
| Gross margin | % | +54.09% | +52.98% | ||||||
| FCF/Sales | % | +8.66% | +8.13% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | -78.38% | -76.88% | ||||||
| Sales Growth YoY | % | -2.92% | -4.31% | ||||||
| Net Income Growth YoY | % | -78.36% | -75.81% | ||||||
| FCF Growth | % | -8.50% | -15.31% | ||||||
| Operating Profit Growth | % | -13.53% | -20.46% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | +4.73% | +0.58% | ||||||
| Dividend Growth | % | -69.64% | -92.86% | ||||||
| Payout Ratio | % | +46.87% | +8.87% | ||||||
| FCF/Debt | x | 0.06 | 0.06 | ||||||
| Net Debt/EBITDA | x | 6.41 | 5.68 | ||||||
| EBIT/Net interest | x | 2.55 | 2.53 | ||||||
| Net debt/market cap | % | +4.67% | +2.37% | ||||||
| Net debt/Equity | x | 10.78 | 7.38 | ||||||
| Gross debt/equity | x | 11.70 | 8.50 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Organon & Co., a global pharmaceutical enterprise, is dedicated to developing and delivering a wide array of prescription therapies. Its women's health division features reproductive care products, encompassing birth control and fertility treatments, notably Nexplanon/Implanon, an extended-duration contraceptive. The company's biosimilars collection includes three immune-related medications (Brenzys, Renflexis, Hadlima) and two cancer therapies (Ontruzant, Aybintio). Additionally, Organon provides cardiovascular medications, such as cholesterol-reducing drugs (Zetia, Ezetrol, Vytorin, Inegy, Rosuzet, Zocor) and treatments for high blood pressure (Cozaar, Hyzaar). Their respiratory product line addresses asthma symptoms with brands like Singulair, Dulera, Zenhale, and Asmanex, and manages seasonal allergies through Singulair, Nasonex, Clarinex, and Aerius. Furthermore, their offerings extend to dermatological care (Diprosone, Elocon), bone strengthening (Fosamax), and non-narcotic pain relief (Arcoxia, Diprospan, Celestone). The portfolio also comprises Proscar for treating symptomatic benign prostatic hyperplasia and Propecia for combating male pattern hair loss. The company's products are primarily distributed to pharmaceutical wholesalers, retailers, medical facilities, government entities, and various managed healthcare organizations, including health maintenance organizations and pharmacy benefit managers. Organon & Co. was established in 2020 and is headquartered in Jersey City, New Jersey.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Organon & Co., a global pharmaceutical enterprise, is dedicated to developing and delivering a wide array of prescription therapies. Its women's health division features reproductive care products, encompassing birth control and fertility treatments, notably Nexplanon/Implanon, an extended-duration contraceptive. The company's biosimilars collection includes three immune-related medications (Brenzys, Renflexis, Hadlima) and two cancer therapies (Ontruzant, Aybintio). Additionally, Organon provides cardiovascular medications, such as cholesterol-reducing drugs (Zetia, Ezetrol, Vytorin, Inegy, Rosuzet, Zocor) and treatments for high blood pressure (Cozaar, Hyzaar). Their respiratory product line addresses asthma symptoms with brands like Singulair, Dulera, Zenhale, and Asmanex, and manages seasonal allergies through Singulair, Nasonex, Clarinex, and Aerius. Furthermore, their offerings extend to dermatological care (Diprosone, Elocon), bone strengthening (Fosamax), and non-narcotic pain relief (Arcoxia, Diprospan, Celestone). The portfolio also comprises Proscar for treating symptomatic benign prostatic hyperplasia and Propecia for combating male pattern hair loss. The company's products are primarily distributed to pharmaceutical wholesalers, retailers, medical facilities, government entities, and various managed healthcare organizations, including health maintenance organizations and pharmacy benefit managers. Organon & Co. was established in 2020 and is headquartered in Jersey City, New Jersey.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free